The Citywide Colorectal Cancer Control Coalition (C5) is a group of public health professionals, clinicians, non-profit partners and researchers with expertise in colorectal cancer prevention that advises the NYC Department of Health in its mission to prevent and control colorectal cancer.
This public-private partnership offers strategic direction and expertise on Health Department initiatives, including educational campaigns, clinical guidelines and clinical practice improvement. C5 helps disseminate Health Department programs to stakeholders, working to increase awareness of and screening for colorectal cancer.
Join the Citywide Colorectal Cancer Control Coalition (C5)
C5 Membership Benefits
C5 Membership Responsibilities
Membership Policy
The C5 is composed of both individuals who solely represent themselves and individuals who represent institutions, agencies, organizations, or corporations. All of these individuals share a common interest in colorectal cancer.
Becoming a member: Those interested in becoming a member can directly request membership in the C5 by completing the C5 membership form online (Join the Citywide Colorectal Cancer Control Coalition), which will be reviewed by C5 program staff and co-chairs of the C5 Steering and C5 Membership Committees for approval.
Active members may participate in all C5 meetings and activities, including, but not limited to, receiving mailings and notices, joining C5 Subcommittees, voting, and holding elected office within the C5. To maintain active membership, active members are expected to attend one general membership meeting yearly (C5 Summit). Active members are encouraged to participate in at least one C5 Subcommittee.
Eligibility: Individuals eligible for active membership are researchers, educators, healthcare providers, cancer survivors, cancer patients undergoing treatment, patient navigators, administrators, public health workers, and others in roles focused on colorectal cancer, or who represent institutions, agencies, or organizations working toward colorectal cancer prevention, without a limit on the number of individuals per organization. Corporations or industries, and individuals representing corporations or industries, are not eligible for active membership but are eligible for associate membership. Individuals as described above who are also employed by corporations or industries, but who do not represent those corporations or industries, are eligible for active membership but must fully disclose any conflicts of interest.
Associate members may receive C5 mailings and notices, and may attend one general membership meeting yearly, the C5 Summit, but do not hold privileges of voting nor can they hold elected office within C5.
Eligibility: An interested individual or organization that does not qualify to be, or does not desire to be, an active member may apply for associate membership, with a limit of up to two associate members per qualifying corporation or industry represented. Those businesses that have affiliation with cancer prevention and screening products that aid colorectal cancer screening, prevention and treatment are eligible, and the efficacy of those products must be supported by scientific research.
To maintain associate membership, associate members that are corporations or industry or represent corporations or industry must abide by all of the following criteria: Operate in the New York City area, not solicit products or services to any other C5 members through coalition channels, will not be provided with contact information for other C5 members, and may not use C5 mailing lists or contact information without approval from C5 staff and C5 Steering Committee co-chairs. Associate membership in C5 does not allow use of the C5 logo and cannot be used for an endorsement or promotion of a commercial product or for personal financial gain.
Data and Targets
In 2021, the Community Health Survey showed that rate of colon cancer screening for adults ages 45 to 75 in NYC was 63.3% (70.8% among Black non-Latino, 66.6% among White, 62.2% among Latino, and 48.1% among Asian/Pacific Islander adults).
Colorectal cancer screening has contributed to decreased incidence and mortality. However, racial disparities in health outcomes persist. Overall colorectal cancer incidence rates decreased 2.7% yearly from 57.7 to 35.5 per /100,000 population from 2000 to 2018. Mortality rates decreased 3.3% yearly from 19.0 to 10.4 overall, at similar rates for all racial/ethnic groups in NYC from 2001 to 2018. However, colorectal cancer incidence remained higher among Black non-Latino New Yorkers (40.5 per 100,000) than among White (38.9), Latino (32.8) and Asian New Yorkers (35.0) from 2014 to 2018. Black non-Latino New Yorkers also had higher mortality rates (14.8), than White (11.8), Latino (9.8) and Asian New Yorkers (8.5) from 2014 to 2018.
Further C5 efforts are needed to reach the goals of equity in colorectal cancer health outcomes and to achieve the national target of 80% screened.
Webinars
Watch: Practical Approaches to Improving CRC Screening Rates in the Community Healthcare Setting
Watch: Evidence and Implementation of New Colon Cancer Screening Guidelines
Watch: Colorectal Cancer Screening in the Post-Pandemic Era
NYC Colorectal Cancer Screening Recommendations
C5 advises the Health Department in the development of colorectal cancer screening recommendations specifically tailored to the local health care environment. In 2020, these local recommendations were updated to address new data on increasing risk of colon cancer at younger ages and to increase screening rates, by encouraging patient choice and promoting shared decision making.
Recommendations for NYC health care providers:
Direct Endoscopic Referral System
C5 created the Direct Referral for Screening Colonoscopy (DERS) form to streamline referrals for colonoscopies by eliminating pre-procedure consultations for eligible patients.
Primary care physicians can use the DERS form to assess their patients and identify those who are eligible for direct referral for colonoscopy. A referral that takes only one visit is more likely to result in a patient following through with a colonoscopy.
Colonoscopy Quality Initiative
From 2011 to 2015, the Colonoscopy Quality Initiative (CQI) improved the quality of screening colonoscopies in the city and identified disparities in the quality of screening colonoscopies. The Health Department collected and analyzed data and disseminated collected performance reports to participating providers. Over the course of the initiative, nearly 300 endoscopists representing 21 sites reported site-level information on eight quality measures for roughly 95,000 screening colonoscopies. The Health Department also provided technical assistance to support accurate and complete data submission.
CQI is funded by the Centers for Disease Control and Prevention, the New York State Department of Health and the Fund of Public Health in New York.
Since 2003, C5 summits have brought together leading professionals and stakeholders in colorectal cancer prevention and control. The summits offer an opportunity for experts at all levels of care to meet and develop new tools and initiatives to increase colorectal cancer screening rates in the city.
Past Summits
Steering Committee
The Steering Committee governs C5 coalition operations, oversees subcommittees and provides recommendations to the Health Department. This committee also plans colorectal cancer prevention initiatives that stakeholders can implement in their respective institutions or programs. Additionally, it confirms new subcommittees, identifies new members and expands the reach of the City’s colorectal cancer initiatives.
Membership Committee
The Membership Committee oversees new member outreach and communication to increase citywide participation in C5 colorectal cancer activities. Membership can be requested at the link: Join the Citywide Colorectal Cancer Control Coalition (C5).
CRC Risk Assessment and Screening Committee
The Risk Assessment and Screening Committee focuses on appropriate risk assessment and increased adherence to CRC screening across all racial and ethnic groups in NYC. Approaches include improving access to care and decreasing disparities by providing patients with more accessible methods.
Colonoscopy Quality Committee
The Colonoscopy Quality Committee aims to improve the quality of screening colonoscopy by developing educational initiatives and tools for providers and their staff.
Community Health Center Committee
The Community Health Center Committee works to improve access to appropriate, timely and quality screening colonoscopies for uninsured patients at community health centers. This committee supports the work of the NYC Community Cares Project.
Screening Guidelines Committee
Since 2003, the Health Department has issued NYC-specific colorectal cancer screening guidelines (PDF). The Screening Guidelines Committee is an advisory panel that reviews these guidelines and recommends revisions as necessary.
Health Equity Committee
As part of the City’s efforts to advance health equity, this committee examines the health inequities relating to colorectal cancer screening, including racial/ethnic and socioeconomic disparities.
80% Screened Committee
The 80% Screened Committee strategizes how C5 can achieve its goal of having 80% of eligible patients in the city receive colorectal cancer screenings.
C5 Publications
Publications are listed in reverse chronological order based on publication date.
Patient Resources
Provider Resources